Navigation Links
Agilent Technologies and A*STAR launch all-in-one drug screening platform
Date:7/21/2011

Agilent Technologies Inc. (NYSE: A) and A*STAR's Experimental Therapeutics Centre (ETC) today announced the launch of a drug screening platform within ETC's new Singapore Screening Centre. This partnership will provide a full spectrum of state-of-the-art automation technologies to biomedical researchers, enabling highly efficient drug screening in one location.

The Singapore Screening Centre conducts high-throughput screening to identify potential drug candidates against disease, using a library of over 300,000 chemical compounds. It now employs Agilent's dual BioCel 1200 integrated system, which automates and coordinates the various processes of high-throughput screening, including compound management, assay plate preparation and experiment replication, to ensure high-quality data while saving time and reducing the possibility of human error.

"The location of Agilent's technology platform within ETC's newly set up Singapore Screening Centre will not only enhance our ability to produce proprietary drugs for Singapore, but also enable us to engage a diversity of biomedical research players from across the world," said Dr. Alex Matter, CEO of ETC. "We expect collaborations with top private sector partners such as Agilent will go a long way to accelerate the development of medical solutions."

The centerpiece of Agilent's BioCel System is a Direct Drive Robot (DDR) that provides significant advantages in speed and ease of use with its one-touch teaching and innovative design. The BioCel system is also customised specifically to ETC's requirements, linking the instruments to ETC's laboratory information management system so that the BioCel database and sample inventory are synchronised and up to date.

The new platform will boost ongoing drug discovery projects at the Singapore Screening Center, including a collaboration with Duke University and the National University of Singapore Graduate Medical School to screen for novel gastric cancer medicines; and another with DSO National Laboratories and A*STAR's Genome Institute of Singapore to discover anti-bacterial drugs using a novel whole animal-screening platform.

"ETC is a leading research institution in Singapore and we look forward to working closely with them to collectively drive drug discovery research," said Yvonne Linney, vice president and general manager, Agilent Automation Solutions Group. "We continue to see growth and opportunities for automated solutions in both Asia and the pharmaceutical markets as a whole."

Singapore has built up strong scientific foundations and capabilities in translational and clinical research to support industry efforts to accelerate the drug discovery process with next-generation technologies. Today, leading pharmaceutical, biotechnology and medical technology companies have invested in more than 50 commercial-scale facilities in Singapore. In 2009, Agilent opened a life sciences manufacturing facility in its Yishun, Singapore campus. The facility expanded Agilent's presence in the region and brought it closer to its Asia Pacific customer base.


'/>"/>

Contact: Adela Foo
adela_foo@a-star.edu.sg
656-826-6218
Agency for Science, Technology and Research (A*STAR), Singapore
Source:Eurekalert

Related biology news :

1. Agilent Technologies Expands Agreement to Offer AMDeC Members Preferential Pricing on Products Through AMDeC F.I.R.S.T.™ Vendor Partnership Program
2. Ambry Genetics Announces Certified Service Provider Status for Agilent Microarrays
3. Laser, electric fields combined for new lab-on-chip technologies
4. Iowa State hybrid lab combines technologies to make biorenewable fuels and products
5. Reportlinker Adds Biometrics: Technologies and Global Markets
6. How natures best ideas inspire innovative new technologies
7. Young Caltech engineers recognized for innovative work in disease diagnostic technologies
8. Nottingham success in green technologies awards
9. From Disruptive to Productive: Unisys Predicts 2011 to be Year of Practical Application of Cutting-Edge Technologies
10. Reportlinker Adds Biometrics: Technologies and Global Markets
11. The CLEAR Program is Back and Oberthur Technologies Remains a Key Partner
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... (NYSE: DAL ) customers now can use fingerprints instead of ... Airport (DCA). ... Delta launches biometrics to board aircraft at Reagan Washington National Airport ... Delta,s biometric boarding pass experience that launched in May ... boarding process to allow eligible Delta SkyMiles Members who are enrolled in ...
(Date:5/23/2017)... , May 23, 2017  Hunova, the first robotic gym for the ... been officially launched in Genoa, Italy . The first ... and the USA . The technology was developed ... market by the IIT spin-off Movendo Technology thanks to a 10 million ... News Release, please click: ...
(Date:4/24/2017)... , April 24, 2017 Janice ... partner with  Identity Strategy Partners, LLP (IdSP) , ... or without President Trump,s March 6, 2017 ... Entry , refugee vetting can be instilled with greater ... (Right now, all refugee applications are suspended by ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... ... eye wash is a basic first aid supply for any work environment, but most personal ... rinse first if a dangerous substance enters both eyes? It’s one less decision, and likely ... dual eye piece. , “Whether its dirt and debris, or an acid or alkali, getting ...
(Date:10/11/2017)... 2017  VMS BioMarketing, a leading provider of patient support ... Nurse Educator (CNE) network, which will launch this week. The ... health care professionals to enhance the patient care experience by ... other health care professionals to help women who have been ... ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... implantation and pregnancy rates in frozen and fresh in vitro fertilization (IVF) ... and maternal age to IVF success. , After comparing the results from the ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that ... Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital Los ...
Breaking Biology Technology: